Showing 4 of 4 recruiting trials for “embryonal-rhabdomyosarcoma”
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
👨⚕️ Chandrika Behura, MD, Penn State Health Children's Hospital📍 20 sites📅 Started Oct 2024View details ↗
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
👨⚕️ Lars Wagner, M.D., Duke University Children's Hospital & Health Center📍 8 sites📅 Started Oct 2021View details ↗
Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
👨⚕️ Svetlana Kulyova, MD, Phd, Head of Children's Oncology Department📍 1 site📅 Started May 2021View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →